Abiomed, Inc.
ABMD · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | -5.29 | 1.97 | -4.65 |
| FCF Yield | 0.07% | 0.54% | 0.42% | 0.51% |
| EV / EBITDA | 169.41 | 152.74 | 198.73 | 226.29 |
| Quality | ||||
| ROIC | 2.84% | 3.30% | 3.42% | 3.33% |
| Gross Margin | 81.62% | 81.01% | 80.93% | 81.76% |
| Cash Conversion Ratio | 0.13 | 1.25 | 1.31 | 1.98 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.19% | 9.80% | 7.06% | 6.04% |
| Free Cash Flow Growth | -87.26% | -4.31% | -23.72% | 57.47% |
| Safety | ||||
| Net Debt / EBITDA | -2.82 | -2.48 | -1.77 | -2.01 |
| Interest Coverage | 0.72 | 17.51 | 6.66 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.48 | 0.55 | 0.55 | 0.53 |
| Cash Conversion Cycle | 155.65 | 133.18 | 132.77 | 140.51 |